BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011;37:63-74. [PMID: 20570444 DOI: 10.1016/j.ctrv.2010.05.001] [Cited by in Crossref: 315] [Cited by in F6Publishing: 305] [Article Influence: 26.3] [Reference Citation Analysis]
Number Citing Articles
1 Gao R, Song J, Sun L, Wu Z, Yi X, Zhang S, Huang L, Ma J, Han C. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. Front Pharmacol 2022;13:920165. [DOI: 10.3389/fphar.2022.920165] [Reference Citation Analysis]
2 Mohammadzadeh V, Rahiman N, Hosseinikhah SM, Barani M, Rahdar A, Jaafari MR, Sargazi S, Zirak MR, Pandey S, Bhattacharjee R, Gupta AK, Thakur VK, Sibuh BZ, Gupta PK. Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: An update. Journal of Drug Delivery Science and Technology 2022;73:103459. [DOI: 10.1016/j.jddst.2022.103459] [Reference Citation Analysis]
3 Zahraie N, Perota G, Dehdari Vais R, Sattarahmady N. Simultaneous chemotherapy/sonodynamic therapy of the melanoma cancer cells using a gold-paclitaxel nanostructure. Photodiagnosis Photodyn Ther 2022;39:102991. [PMID: 35779857 DOI: 10.1016/j.pdpdt.2022.102991] [Reference Citation Analysis]
4 Lidonnici J, Santoro MM, Oberkersch RE. Cancer-Induced Metabolic Rewiring of Tumor Endothelial Cells. Cancers (Basel) 2022;14:2735. [PMID: 35681715 DOI: 10.3390/cancers14112735] [Reference Citation Analysis]
5 Jiang Z, Liu Y, Shi R, Feng X, Xu W, Zhuang X, Ding J, Chen X. Versatile Polymer-Initiating Biomineralization for Tumor Blockade Therapy. Adv Mater 2022;34:e2110094. [PMID: 35202501 DOI: 10.1002/adma.202110094] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Morris RM, Mortimer TO, O'Neill KL. Cytokines: Can Cancer Get the Message? Cancers (Basel) 2022;14:2178. [PMID: 35565306 DOI: 10.3390/cancers14092178] [Reference Citation Analysis]
7 Halkola AS, Aittokallio T, Parvinen K. Tumor microenvironment as a metapopulation model: the effects of angiogenesis, emigration and treatment modalities. J Theor Biol 2022;:111147. [PMID: 35489642 DOI: 10.1016/j.jtbi.2022.111147] [Reference Citation Analysis]
8 Chen L, Wang S, Feng Y, Yu J, Coudyzer W, Van Ongeval C, Geng L, Li Y, Ni Y. Development and characterization of a chick embryo chorioallantoic membrane (CAM) based platform for evaluation of vasoactive medications. Microvasc Res 2022;:104372. [PMID: 35483521 DOI: 10.1016/j.mvr.2022.104372] [Reference Citation Analysis]
9 Sharma D, Leong KX, Czarnota GJ. Application of Ultrasound Combined with Microbubbles for Cancer Therapy. Int J Mol Sci 2022;23:4393. [PMID: 35457210 DOI: 10.3390/ijms23084393] [Reference Citation Analysis]
10 Wu Q, Tsai HI, Zhu H, Wang D. The Entanglement between Mitochondrial DNA and Tumor Metastasis. Cancers (Basel) 2022;14:1862. [PMID: 35454769 DOI: 10.3390/cancers14081862] [Reference Citation Analysis]
11 Al-zoubi MS, Al-zoubi RM. Nanomedicine Tactics in Cancer Treatment: Challenge and Hope. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103677] [Reference Citation Analysis]
12 Sathiyanadan K, Alonso F, Domingos-Pereira S, Santoro T, Hamard L, Cesson V, Meda P, Nardelli-Haefliger D, Haefliger JA. Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth. Int J Mol Sci 2022;23:2930. [PMID: 35328350 DOI: 10.3390/ijms23062930] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Theotoka D, Liu Z, Wall S, Galor A, Al Bayyat GJ, Feuer W, Jianhua W, Karp CL. Optical coherence tomography angiography in the evaluation of vascular patterns of ocular surface squamous neoplasia during topical medical treatment. The Ocular Surface 2022. [DOI: 10.1016/j.jtos.2022.03.006] [Reference Citation Analysis]
14 Giordo R, Wehbe Z, Paliogiannis P, Eid AH, Mangoni AA, Pintus G. Nano-targeting vascular remodeling in cancer: Recent developments and future directions. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Elgazery NS, Elelamy AF, Bobescu E, Ellahi R. How do artificial bacteria behave in magnetized nanofluid with variable thermal conductivity: application of tumor reduction and cancer cells destruction. HFF 2022;ahead-of-print. [DOI: 10.1108/hff-11-2021-0722] [Reference Citation Analysis]
16 Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting CANCER angiogenesis and immune checkpoint networks for improved tumor immunity. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Michon S, Rodier F, Yu FTH. Targeted Anti-Cancer Provascular Therapy Using Ultrasound, Microbubbles, and Nitrite to Increase Radiotherapy Efficacy. Bioconjug Chem 2022. [PMID: 34990112 DOI: 10.1021/acs.bioconjchem.1c00510] [Reference Citation Analysis]
18 Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021;14:41. [PMID: 35056937 DOI: 10.3390/pharmaceutics14010041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Reipsch F, Biersack B, Lucas H, Schobert R, Mueller T. Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models. Int J Mol Sci 2021;22:13082. [PMID: 34884888 DOI: 10.3390/ijms222313082] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wu Y, Zhou Y, Qin X, Liu Y. From cell spheroids to vascularized cancer organoids: Microfluidic tumor-on-a-chip models for preclinical drug evaluations. Biomicrofluidics 2021;15:061503. [PMID: 34804315 DOI: 10.1063/5.0062697] [Reference Citation Analysis]
21 Hussen BM, Abdullah ST, Rasul MF, Salihi A, Ghafouri-Fard S, Hidayat HJ, Taheri M. MicroRNAs: Important Players in Breast Cancer Angiogenesis and Therapeutic Targets. Front Mol Biosci 2021;8:764025. [PMID: 34778378 DOI: 10.3389/fmolb.2021.764025] [Reference Citation Analysis]
22 Wordeman L, Vicente JJ. Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles. Cancers (Basel) 2021;13:5650. [PMID: 34830812 DOI: 10.3390/cancers13225650] [Reference Citation Analysis]
23 Wang WY, Kent RN 3rd, Huang SA, Jarman EH, Shikanov EH, Davidson CD, Hiraki HL, Lin D, Wall MA, Matera DL, Shin JW, Polacheck WJ, Shikanov A, Baker BM. Direct comparison of angiogenesis in natural and synthetic biomaterials reveals that matrix porosity regulates endothelial cell invasion speed and sprout diameter. Acta Biomater 2021;135:260-73. [PMID: 34469789 DOI: 10.1016/j.actbio.2021.08.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
24 Yang L, Zhang W, Qiu Q, Su Z, Tang M, Bai P, Si W, Zhu Z, Liu Y, Yang J, Kuang S, Liu J, Yan W, Shi M, Ye H, Yang Z, Chen L. Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity. J Med Chem 2021;64:15379-401. [PMID: 34648295 DOI: 10.1021/acs.jmedchem.1c01451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Brahmbhatt H, MacDiarmid JA. Bacterial minicells to the rescue: cyto-Immunotherapy for the treatment of late stage cancers with minimal to no toxicity. Microb Biotechnol 2022;15:91-4. [PMID: 34665932 DOI: 10.1111/1751-7915.13952] [Reference Citation Analysis]
26 Yu X, Su Q, Chang X, Chen K, Yuan P, Liu T, Tian R, Bai Y, Zhang Y, Chen X. Multimodal obstruction of tumorigenic energy supply via bionic nanocarriers for effective tumor therapy. Biomaterials 2021;278:121181. [PMID: 34653932 DOI: 10.1016/j.biomaterials.2021.121181] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Song J, Choi H, Koh SK, Park D, Yu J, Kang H, Kim Y, Cho D, Jeon NL. High-Throughput 3D In Vitro Tumor Vasculature Model for Real-Time Monitoring of Immune Cell Infiltration and Cytotoxicity. Front Immunol 2021;12:733317. [PMID: 34630415 DOI: 10.3389/fimmu.2021.733317] [Reference Citation Analysis]
28 Bhat SM, Badiger VA, Vasishta S, Chakraborty J, Prasad S, Ghosh S, Joshi MB. 3D tumor angiogenesis models: recent advances and challenges. J Cancer Res Clin Oncol 2021;147:3477-94. [PMID: 34613483 DOI: 10.1007/s00432-021-03814-0] [Reference Citation Analysis]
29 He Z, Zhang S. Tumor-Associated Macrophages and Their Functional Transformation in the Hypoxic Tumor Microenvironment. Front Immunol 2021;12:741305. [PMID: 34603327 DOI: 10.3389/fimmu.2021.741305] [Reference Citation Analysis]
30 Cohen-erner M, Khandadash R, Hof R, Shalev O, Antebi A, Cyjon A, Kanakov D, Nyska A, Goss G, Hilton J, Peer D. Fe 3 O 4 Nanoparticles and Paraffin Wax as Phase Change Materials Embedded in Polymer Matrixes for Temperature-Controlled Magnetic Hyperthermia. ACS Appl Nano Mater 2021;4:11187-98. [DOI: 10.1021/acsanm.1c02676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Ulrich L, Held KG, Jaeger M, Frenz M, Akarçay HG. Reliability assessment for blood oxygen saturation levels measured with optoacoustic imaging. J Biomed Opt 2020;25:1-15. [PMID: 32323509 DOI: 10.1117/1.JBO.25.4.046005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Guo Y, Wang H, Gerberich JL, Odutola SO, Charlton-Sevcik AK, Li M, Tanpure RP, Tidmore JK, Trawick ML, Pinney KG, Mason RP, Liu L. Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment. Cancers (Basel) 2021;13:4769. [PMID: 34638255 DOI: 10.3390/cancers13194769] [Reference Citation Analysis]
33 Applegate CC, Lowerison MR, Hambley E, Song P, Wallig MA, Erdman JW Jr. Dietary tomato inhibits angiogenesis in TRAMP prostate cancer but is not protective with a Western-style diet in this pilot study. Sci Rep 2021;11:18548. [PMID: 34535690 DOI: 10.1038/s41598-021-97539-2] [Reference Citation Analysis]
34 Banerjee S, Mahmud F, Deng S, Ma L, Yun MK, Fakayode SO, Arnst KE, Yang L, Chen H, Wu Z, Lukka PB, Parmar K, Meibohm B, White SW, Wang Y, Li W, Miller DD. X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. J Med Chem 2021;64:13072-95. [PMID: 34406768 DOI: 10.1021/acs.jmedchem.1c01202] [Reference Citation Analysis]
35 Haque MR, Rempert TH, Al-Hilal TA, Wang C, Bhushan A, Bishehsari F. Organ-Chip Models: Opportunities for Precision Medicine in Pancreatic Cancer. Cancers (Basel) 2021;13:4487. [PMID: 34503294 DOI: 10.3390/cancers13174487] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Brloznik M, Boc N, Cemazar M, Bosnjak M, Savarin M, Kejzar N, Sersa G, Pavlin D, Kranjc Brezar S. Contrast-enhanced ultrasound for evaluation of tumor perfusion and outcome following treatment in a murine melanoma model. Bioelectrochemistry 2021;142:107932. [PMID: 34474205 DOI: 10.1016/j.bioelechem.2021.107932] [Reference Citation Analysis]
37 Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, Xu Y, Shao J, Wang W, Cai Z. Nanoparticle-Mediated Targeted Drug Delivery to Remodel Tumor Microenvironment for Cancer Therapy. Int J Nanomedicine 2021;16:5811-29. [PMID: 34471353 DOI: 10.2147/IJN.S321416] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Luengo Morato Y, Ovejero Paredes K, Lozano Chamizo L, Marciello M, Filice M. Recent Advances in Multimodal Molecular Imaging of Cancer Mediated by Hybrid Magnetic Nanoparticles. Polymers (Basel) 2021;13:2989. [PMID: 34503029 DOI: 10.3390/polym13172989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Kim JJ, Kim JY, Suh HB, Hwangbo L, Lee NK, Kim S, Lee JW, Choo KS, Nam KJ, Kang T, Park H. Characterization of breast cancer subtypes based on quantitative assessment of intratumoral heterogeneity using dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging. Eur Radiol 2021. [PMID: 34345946 DOI: 10.1007/s00330-021-08166-4] [Reference Citation Analysis]
40 Tang LJW, Zaseela A, Toh CCM, Adine C, Aydar AO, Iyer NG, Fong ELS. Engineering stromal heterogeneity in cancer. Adv Drug Deliv Rev 2021;175:113817. [PMID: 34087326 DOI: 10.1016/j.addr.2021.05.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Bui TM, Yalom LK, Sumagin R. Tumor-associated neutrophils: orchestrating cancer pathobiology and therapeutic resistance. Expert Opin Ther Targets 2021;25:573-83. [PMID: 34236924 DOI: 10.1080/14728222.2021.1954162] [Reference Citation Analysis]
42 Brloznik M, Boc N, Cemazar M, Sersa G, Bosnjak M, Brezar SK, Pavlin D. Tumor perfusion evaluation using dynamic contrast-enhanced ultrasound after electrochemotherapy and IL-12 plasmid electrotransfer in murine melanoma. Sci Rep 2021;11:13446. [PMID: 34188103 DOI: 10.1038/s41598-021-92820-w] [Reference Citation Analysis]
43 Owen J, Logan K, Nesbitt H, Able S, Vasilyeva A, Bluemke E, Kersemans V, Smart S, Vallis KA, Mchale AP, Callan JF, Stride E. Orally administered oxygen nanobubbles enhance tumor response to sonodynamic therapy. Nano Select 2022;3:394-401. [DOI: 10.1002/nano.202100038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Wang WY, Lin D, Jarman EH, Polacheck WJ, Baker BM. Functional angiogenesis requires microenvironmental cues balancing endothelial cell migration and proliferation. Lab Chip 2020;20:1153-66. [PMID: 32100769 DOI: 10.1039/c9lc01170f] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
45 Movahedi F, Gu W, Soares CP, Xu ZP. Encapsulating Anti-Parasite Benzimidazole Drugs into Lipid-Coated Calcium Phosphate Nanoparticles to Efficiently Induce Skin Cancer Cell Apoptosis. Front Nanotechnol 2021;3:693837. [DOI: 10.3389/fnano.2021.693837] [Reference Citation Analysis]
46 Song L, Li C, Yin J. Texture Analysis Using Semiquantitative Kinetic Parameter Maps from DCE-MRI: Preoperative Prediction of HER2 Status in Breast Cancer. Front Oncol 2021;11:675160. [PMID: 34168994 DOI: 10.3389/fonc.2021.675160] [Reference Citation Analysis]
47 Swamy K. Vascular-immuno-phenotypic (VIP) model for locally advanced and oligo-metastatic cancer: A hypothesis. Med Hypotheses 2021;152:110618. [PMID: 34102599 DOI: 10.1016/j.mehy.2021.110618] [Reference Citation Analysis]
48 Dasgupta S, Ghosh T, Dhar J, Bhuniya A, Nandi P, Das A, Saha A, Das J, Guha I, Banerjee S, Chakravarti M, Dasgupta PS, Alam N, Chakrabarti J, Majumdar S, Chakrabarti P, Storkus WJ, Baral R, Bose A. RGS5-TGFβ-Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth. Cell Death Differ 2021. [PMID: 34012071 DOI: 10.1038/s41418-021-00801-3] [Reference Citation Analysis]
49 Hanley T, Vankayala R, Lee CH, Tang JC, Burns JM, Anvari B. Phototheranostics Using Erythrocyte-Based Particles. Biomolecules 2021;11:729. [PMID: 34068081 DOI: 10.3390/biom11050729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
50 Ginghină O, Hudiță A, Zaharia C, Tsatsakis A, Mezhuev Y, Costache M, Gălățeanu B. Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. Materials (Basel) 2021;14:2440. [PMID: 34066710 DOI: 10.3390/ma14092440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Damiana TST, Dalm SU. Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. Pharmaceutics 2021;13:674. [PMID: 34067215 DOI: 10.3390/pharmaceutics13050674] [Reference Citation Analysis]
52 Sebestyén A, Kopper L, Dankó T, Tímár J. Hypoxia Signaling in Cancer: From Basics to Clinical Practice. Pathol Oncol Res 2021;27:1609802. [PMID: 34257622 DOI: 10.3389/pore.2021.1609802] [Reference Citation Analysis]
53 Fatima H, Charinpanitkul T, Kim KS. Fundamentals to Apply Magnetic Nanoparticles for Hyperthermia Therapy. Nanomaterials (Basel) 2021;11:1203. [PMID: 34062851 DOI: 10.3390/nano11051203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
54 Liu L, O'Kelly D, Schuetze R, Carlson G, Zhou H, Trawick ML, Pinney KG, Mason RP. Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors. Molecules 2021;26:2551. [PMID: 33925707 DOI: 10.3390/molecules26092551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Charalambous A, Mico V, McVeigh LE, Marston G, Ingram N, Volpato M, Peyman SA, McLaughlan JR, Wierzbicki A, Loadman PM, Bushby RJ, Markham AF, Evans SD, Coletta PL. Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, combretastatin A4. Nanomedicine 2021;36:102401. [PMID: 33894396 DOI: 10.1016/j.nano.2021.102401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Wan PK, Ryan AJ, Seymour LW. Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol Ther 2021;29:1668-82. [PMID: 33845199 DOI: 10.1016/j.ymthe.2021.04.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Ji G, Li Q, Shen Y, Gan J, Xu L, Wang Y, Luo H, Yang Y, Dong E, Zhang G, Liu B, Yue X, Zhang W, Yang H. Eradication of large established tumors by drug-loaded bacterial particles via a neutrophil-mediated mechanism. J Control Release 2021;334:52-63. [PMID: 33878368 DOI: 10.1016/j.jconrel.2021.04.015] [Reference Citation Analysis]
58 Nguyen NH, Dang LH, Doan P, Huynh CK, Nguyen CK, Nguyen BT, Nguyen NT, Tran NQ. Polyacrylic-conjugated polyamidoamine G4.0 dendrimer as a potential nanocarrier for effective delivery of cisplatin. Bull Mater Sci 2021;44. [DOI: 10.1007/s12034-021-02382-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zhao Y, Ting KK, Coleman P, Qi Y, Chen J, Vadas M, Gamble J. The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking. Cancers (Basel) 2021;13:1724. [PMID: 33917287 DOI: 10.3390/cancers13071724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Balakrishnan PB, Sweeney EE. Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors. Front Immunol 2021;12:600659. [PMID: 33833751 DOI: 10.3389/fimmu.2021.600659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Zhu H, Li W, Shuai W, Liu Y, Yang L, Tan Y, Zheng T, Yao H, Xu J, Zhu Z, Yang DH, Chen ZS, Xu S. Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. Eur J Med Chem 2021;216:113316. [PMID: 33676300 DOI: 10.1016/j.ejmech.2021.113316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 De Paz Linares GA, Opperman RM, Majumder M, Lala PK. Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis. Cancers (Basel) 2021;13:942. [PMID: 33668160 DOI: 10.3390/cancers13050942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Chen L, Wang S, Feng Y, Zhang J, Du Y, Zhang J, Ongeval CV, Ni Y, Li Y. Utilisation of Chick Embryo Chorioallantoic Membrane as a Model Platform for Imaging-Navigated Biomedical Research. Cells 2021;10:463. [PMID: 33671534 DOI: 10.3390/cells10020463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Karmacharya MB, Sultan LR, Sehgal CM. Photoacoustic monitoring of oxygenation changes induced by therapeutic ultrasound in murine hepatocellular carcinoma. Sci Rep 2021;11:4100. [PMID: 33603035 DOI: 10.1038/s41598-021-83439-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Huang D, Sun L, Huang L, Chen Y. Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect. J Pers Med 2021;11:124. [PMID: 33672813 DOI: 10.3390/jpm11020124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
66 Chen J, Yang H, Feng Y, Shi Q, Li Z, Tao Z, Fan J, Jin Y, Li S, Cheng J, Lu X. A single nucleotide mutation drastically increases the expression of tumor-homing NGR-TNFα in the E. coli M15-pQE30 system by improving gene transcription. Appl Microbiol Biotechnol 2021;105:1447-60. [PMID: 33528691 DOI: 10.1007/s00253-021-11136-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
67 Wang Y, Shen N, Wang Y, Zhang Y, Tang Z, Chen X. Self-Amplifying Nanotherapeutic Drugs Homing to Tumors in a Manner of Chain Reaction. Adv Mater 2021;33:e2002094. [PMID: 33382144 DOI: 10.1002/adma.202002094] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
68 Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, Nedaeinia R, Haghjooy Javanmard S, Taherian M, Ahmadlou M, Salehi R, Sadeghi B, Manian M. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int 2021;21:62. [PMID: 33472628 DOI: 10.1186/s12935-020-01719-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
69 Duggan MR, Weaver M, Khalili K. PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging. Aging (Albany NY) 2021;13:1510-27. [PMID: 33472174 DOI: 10.18632/aging.202459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Fernando K, Kwang LG, Lim JTC, Fong ELS. Hydrogels to engineer tumor microenvironments in vitro. Biomater Sci 2021;9:2362-83. [DOI: 10.1039/d0bm01943g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
71 Wooster AL, Girgis LH, Brazeale H, Anderson TS, Wood LM, Lowe DB. Dendritic cell vaccine therapy for colorectal cancer. Pharmacol Res 2021;164:105374. [PMID: 33348026 DOI: 10.1016/j.phrs.2020.105374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Augustin LB, Milbauer L, Hastings SE, Leonard AS, Saltzman DA, Schottel JL. Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer. J Drug Target 2021;29:430-8. [PMID: 33183080 DOI: 10.1080/1061186X.2020.1850739] [Reference Citation Analysis]
73 Esteves M, Monteiro MP, Duarte JA. Role of Regular Physical Exercise in Tumor Vasculature: Favorable Modulator of Tumor Milieu. Int J Sports Med 2021;42:389-406. [PMID: 33307553 DOI: 10.1055/a-1308-3476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Menzel L, Höpken UE, Rehm A. Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth. Front Immunol 2020;11:591741. [PMID: 33343570 DOI: 10.3389/fimmu.2020.591741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Mehanna MM, Sarieddine R, Alwattar JK, Chouaib R, Gali-Muhtasib H. Anticancer Activity of Thymoquinone Cubic Phase Nanoparticles Against Human Breast Cancer: Formulation, Cytotoxicity and Subcellular Localization. Int J Nanomedicine 2020;15:9557-70. [PMID: 33293807 DOI: 10.2147/IJN.S263797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
76 Nazemian S, Nabaei M. Numerical investigation of the effect of vascular network complexity on the efficiency of cryosurgery of a liver tumor. International Journal of Thermal Sciences 2020;158:106569. [DOI: 10.1016/j.ijthermalsci.2020.106569] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Amen TB, Varady NH, Birir A, Hayden BL, Chen AF. Morbidity and mortality of surgically treated pathologic humerus fractures compared to native humerus fractures. J Shoulder Elbow Surg 2021;30:1873-80. [PMID: 33220410 DOI: 10.1016/j.jse.2020.10.024] [Reference Citation Analysis]
78 Cui YJ, Liu C, Ma CC, Ji YT, Yao YL, Tang LQ, Zhang CM, Wu JD, Liu ZP. SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazoles as Potent Tubulin Polymerization Inhibitors. J Med Chem 2020;63:14840-66. [PMID: 33201714 DOI: 10.1021/acs.jmedchem.0c01345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Donlon NE, Sheppard A, Davern M, O'Connell F, Phelan JJ, Power R, Nugent T, Dinneen K, Aird J, Greene J, Nevins Selvadurai P, Bhardwaj A, Foley EK, Ravi N, Donohoe CL, Reynolds JV, Lysaght J, O'Sullivan J, Dunne MR. Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinoma-An Emerging Role for Chemokines. Cancers (Basel) 2020;12:E3356. [PMID: 33202734 DOI: 10.3390/cancers12113356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Duru G, van Egmond M, Heemskerk N. A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. Front Immunol 2020;11:584723. [PMID: 33262763 DOI: 10.3389/fimmu.2020.584723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
81 Haider T, Sandha KK, Soni V, Gupta PN. Recent advances in tumor microenvironment associated therapeutic strategies and evaluation models. Materials Science and Engineering: C 2020;116:111229. [DOI: 10.1016/j.msec.2020.111229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
82 Schoustra SM, Piras D, Huijink R, Op 't Root TJPM, Alink L, Kobold WM, Steenbergen W, Manohar S. Twente Photoacoustic Mammoscope 2: system overview and three-dimensional vascular network images in healthy breasts. J Biomed Opt 2019;24:1-12. [PMID: 31650741 DOI: 10.1117/1.JBO.24.12.121909] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
83 Zaleskis G, Garberytė S, Pavliukevičienė B, Valinčius G, Characiejus D, Mauricas M, Kraśko JA, Žilionytė K, Žvirblė M, Pašukonienė V. Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention. J Cancer 2020;11:6497-506. [PMID: 33046971 DOI: 10.7150/jca.46066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Yu H, Bao Y, Xu C, Chen L, Tang Z. Poly(L-Glutamic Acid)-Drug Conjugates for Chemo- and Photodynamic Combination Therapy. Macromol Biosci 2021;21:e2000192. [PMID: 33043592 DOI: 10.1002/mabi.202000192] [Reference Citation Analysis]
85 Zhuang X, Maione F, Robinson J, Bentley M, Kaul B, Whitworth K, Jumbu N, Jinks E, Bystrom J, Gabriele P, Garibaldi E, Delmastro E, Nagy Z, Gilham D, Giraudo E, Bicknell R, Lee SP. CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth. JCI Insight 2020;5:138808. [PMID: 33004686 DOI: 10.1172/jci.insight.138808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
86 Weishaupt C, Goerge T, Loser K. Activated melanoma vessels: A sticky point for successful immunotherapy. Exp Dermatol 2020;29:1046-54. [PMID: 32998178 DOI: 10.1111/exd.14203] [Reference Citation Analysis]
87 Hall AS, Jacobs JL, Smith EN. Possible osteosarcoma reported from a new world elapid snake and review of reptilian bony tumors. Anat Rec (Hoboken) 2020;303:2955-66. [PMID: 32864868 DOI: 10.1002/ar.24475] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Gupta S, Dwarakanath BS. Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors. Curr Med Chem 2020;27:4002-15. [PMID: 29852858 DOI: 10.2174/0929867325666180601101145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
89 Halpin-Veszeleiova K, Hatfield SM. Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy. Curr Opin Pharmacol 2020;53:84-90. [PMID: 32841869 DOI: 10.1016/j.coph.2020.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
90 Mendes C, Serpa J. Revisiting lactate dynamics in cancer—a metabolic expertise or an alternative attempt to survive? J Mol Med 2020;98:1397-414. [DOI: 10.1007/s00109-020-01965-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Sicard G, Fina F, Fanciullino R, Barlesi F, Ciccolini J. Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. Pharmaceutics 2020;12:E758. [PMID: 32796670 DOI: 10.3390/pharmaceutics12080758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Mao X, Guo Y, Lu Z, Wen F, Liang H, Sun W. Enhanced CT Textures Derived From Computer Mathematic Distribution Analysis Enables Arterial Enhancement Fraction Being an Imaging Biomarker Option of Hepatocellular Carcinoma. Front Oncol 2020;10:1337. [PMID: 32850426 DOI: 10.3389/fonc.2020.01337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Guo F, Cui J. Anti-angiogenesis: Opening a new window for immunotherapy. Life Sci 2020;258:118163. [PMID: 32738363 DOI: 10.1016/j.lfs.2020.118163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
94 Silvestri VL, Henriet E, Linville RM, Wong AD, Searson PC, Ewald AJ. A Tissue-Engineered 3D Microvessel Model Reveals the Dynamics of Mosaic Vessel Formation in Breast Cancer. Cancer Res 2020;80:4288-301. [PMID: 32665356 DOI: 10.1158/0008-5472.CAN-19-1564] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
95 Mrozik KM, Cheong CM, Hewett DR, Noll JE, Opperman KS, Adwal A, Russell DL, Blaschuk OW, Vandyke K, Zannettino ACW. LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib. FASEB Bioadv 2020;2:339-53. [PMID: 32617520 DOI: 10.1096/fba.2019-00073] [Reference Citation Analysis]
96 Perfahl H, Jain HV, Joshi T, Horger M, Malek N, Bitzer M, Reuss M. Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC). Sci Rep 2020;10:10571. [PMID: 32601310 DOI: 10.1038/s41598-020-65012-1] [Reference Citation Analysis]
97 Allen KL, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Tsui P, Li Q. Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models. PLoS One 2020;15:e0234268. [PMID: 32497150 DOI: 10.1371/journal.pone.0234268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Gong F, Yang N, Wang X, Zhao Q, Chen Q, Liu Z, Cheng L. Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics. Nano Today 2020;32:100851. [DOI: 10.1016/j.nantod.2020.100851] [Cited by in Crossref: 68] [Cited by in F6Publishing: 38] [Article Influence: 34.0] [Reference Citation Analysis]
99 Chang WH, Lai AG. The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome. Cancer Lett 2020;487:34-44. [PMID: 32470490 DOI: 10.1016/j.canlet.2020.05.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
100 Salimi L, Akbari A, Jabbari N, Mojarad B, Vahhabi A, Szafert S, Kalashani SA, Soraya H, Nawaz M, Rezaie J. Synergies in exosomes and autophagy pathways for cellular homeostasis and metastasis of tumor cells. Cell Biosci 2020;10:64. [PMID: 32426106 DOI: 10.1186/s13578-020-00426-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
101 Čermák V, Dostál V, Jelínek M, Libusová L, Kovář J, Rösel D, Brábek J. Microtubule-targeting agents and their impact on cancer treatment. Eur J Cell Biol 2020;99:151075. [PMID: 32414588 DOI: 10.1016/j.ejcb.2020.151075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
102 Zhou Y, Chen X, Cao J, Gao H. Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy. J Mater Chem B 2020;8:6765-81. [PMID: 32315375 DOI: 10.1039/d0tb00649a] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
103 Phillips CM, Lima EABF, Woodall RT, Brock A, Yankeelov TE. A hybrid model of tumor growth and angiogenesis: In silico experiments. PLoS One 2020;15:e0231137. [PMID: 32275674 DOI: 10.1371/journal.pone.0231137] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
104 Chen D, Qu X, Shao J, Wang W, Dong X. Anti-vascular nano agents: a promising approach for cancer treatment. J Mater Chem B 2020;8:2990-3004. [PMID: 32211649 DOI: 10.1039/c9tb02957e] [Cited by in Crossref: 13] [Article Influence: 6.5] [Reference Citation Analysis]
105 Winn BA, Devkota L, Kuch B, MacDonough MT, Strecker TE, Wang Y, Shi Z, Gerberich JL, Mondal D, Ramirez AJ, Hamel E, Chaplin DJ, Davis P, Mason RP, Trawick ML, Pinney KG. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. J Nat Prod 2020;83:937-54. [PMID: 32196334 DOI: 10.1021/acs.jnatprod.9b00773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
106 Álvarez R, Aramburu L, Gajate C, Vicente-Blázquez A, Mollinedo F, Medarde M, Peláez R. Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring. Bioorg Chem 2020;98:103755. [PMID: 32200330 DOI: 10.1016/j.bioorg.2020.103755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
107 Sorrin AJ, Kemal Ruhi M, Ferlic NA, Karimnia V, Polacheck WJ, Celli JP, Huang HC, Rizvi I. Photodynamic Therapy and the Biophysics of the Tumor Microenvironment. Photochem Photobiol 2020;96:232-59. [PMID: 31895481 DOI: 10.1111/php.13209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
108 Thébault CJ, Ramniceanu G, Boumati S, Michel A, Seguin J, Larrat B, Mignet N, Ménager C, Doan BT. Theranostic MRI liposomes for magnetic targeting and ultrasound triggered release of the antivascular CA4P. J Control Release 2020;322:137-48. [PMID: 32145266 DOI: 10.1016/j.jconrel.2020.03.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
109 Gold M, Köhler L, Lanzloth C, Andronache I, Anant S, Dandawate P, Biersack B, Schobert R. Synthesis and bioevaluation of new vascular-targeting and anti-angiogenic thieno[2,3-d]pyrimidin-4(3H)-ones. European Journal of Medicinal Chemistry 2020;189:112060. [DOI: 10.1016/j.ejmech.2020.112060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
110 Gong FL, Wang L, Yu LG, Dang YF, Jiang XN, Zhao L, Guo XL. DHPAC, a novel microtubule depolymerizing agent, suppresses angiogenesis and vasculogenic mimicry formation of human non-small cell lung cancer. J Cell Biochem 2020. [PMID: 32056279 DOI: 10.1002/jcb.29690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 Zhang H, Ren Y, Hou L, Chang J, Zhang Z, Zhang H. Positioning Remodeling Nanogels Mediated Codelivery of Antivascular Drug and Autophagy Inhibitor for Cooperative Tumor Therapy. ACS Appl Mater Interfaces 2020;12:6978-90. [PMID: 31951366 DOI: 10.1021/acsami.9b22412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
112 Guo F, Ji G, Li Q, Yang Y, Shui L, Shen Y, Yang H. Bacterial particles retard tumor growth as a novel vascular disrupting agent. Biomedicine & Pharmacotherapy 2020;122:109757. [DOI: 10.1016/j.biopha.2019.109757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Mühlberger M, Unterweger H, Band J, Lehmann C, Heger L, Dudziak D, Alexiou C, Lee G, Janko C. Loading of Primary Human T Lymphocytes with Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles Does Not Impair Their Activation after Polyclonal Stimulation. Cells 2020;9:E342. [PMID: 32024193 DOI: 10.3390/cells9020342] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
114 Kraus Y, Glas C, Melzer B, Gao L, Heise C, Preuße M, Ahlfeld J, Bracher F, Thorn-Seshold O. Isoquinoline-based biaryls as a robust scaffold for microtubule inhibitors. Eur J Med Chem 2020;186:111865. [PMID: 31735573 DOI: 10.1016/j.ejmech.2019.111865] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Zhang M, Ye JJ, Xia Y, Wang ZY, Li CX, Wang XS, Yu W, Song W, Feng J, Zhang XZ. Platelet-Mimicking Biotaxis Targeting Vasculature-Disrupted Tumors for Cascade Amplification of Hypoxia-Sensitive Therapy. ACS Nano 2019;13:14230-40. [PMID: 31714733 DOI: 10.1021/acsnano.9b07330] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
116 Arnst KE, Banerjee S, Wang Y, Chen H, Li Y, Yang L, Li W, Miller DD, Li W. X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone as Potent Tubulin Polymerization Inhibitors. ACS Chem Biol 2019;14:2810-21. [PMID: 31714738 DOI: 10.1021/acschembio.9b00696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
117 Guarino BD, Adapala RK, Kanugula AK, Lenkey NM, Dougherty JA, Paruchuri S, Khan M, Thodeti CK. Extracellular Vesicles From Pathological Microenvironment Induce Endothelial Cell Transformation and Abnormal Angiogenesis via Modulation of TRPV4 Channels. Front Cell Dev Biol 2019;7:344. [PMID: 31921855 DOI: 10.3389/fcell.2019.00344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
118 Li X, Li Y, Lu W, Chen M, Ye W, Zhang D. The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. Cells 2019;8:E1602. [PMID: 31835465 DOI: 10.3390/cells8121602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
119 Cable J, Finley L, Tu BP, Patti GJ, Oliver TG, Vardhana S, Mana M, Ericksen R, Khare S, DeBerardinis R, Stockwell BR, Edinger A, Haigis M, Kaelin W. Leveraging insights into cancer metabolism-a symposium report. Ann N Y Acad Sci 2020;1462:5-13. [PMID: 31792987 DOI: 10.1111/nyas.14274] [Reference Citation Analysis]
120 Kwon J, Rajamahendiran RM, Virani NA, Kunjachan S, Snay E, Harlacher M, Myronakis M, Shimizu S, Shirato H, Czernuszewicz TJ, Gessner R, Berbeco R. Use of 3-D Contrast-Enhanced Ultrasound to Evaluate Tumor Microvasculature After Nanoparticle-Mediated Modulation. Ultrasound Med Biol 2020;46:369-76. [PMID: 31694771 DOI: 10.1016/j.ultrasmedbio.2019.09.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
121 Lee JH, Yoon YC, Seo SW, Choi YL, Kim HS. Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index. Eur Radiol 2020;30:914-24. [PMID: 31630234 DOI: 10.1007/s00330-019-06445-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
122 Deng C, Zhao J, Zhou S, Dong J, Cao J, Gao J, Bai Y, Deng H. The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors. Mol Ther 2020;28:75-88. [PMID: 31672285 DOI: 10.1016/j.ymthe.2019.10.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
123 West C, Slevin F. Tumour Hypoxia. Clinical Oncology 2019;31:595-9. [DOI: 10.1016/j.clon.2019.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
124 Martínez-Poveda B, Torres-Vargas JA, Ocaña MDC, García-Caballero M, Medina MÁ, Quesada AR. The Mediterranean Diet, a Rich Source of Angiopreventive Compounds in Cancer. Nutrients 2019;11:E2036. [PMID: 31480406 DOI: 10.3390/nu11092036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
125 Kwon YM, Je JY, Cha SH, Oh Y, Cho WH. Synergistic combination of chemo‑phototherapy based on temozolomide/ICG‑loaded iron oxide nanoparticles for brain cancer treatment. Oncol Rep 2019;42:1709-24. [PMID: 31436296 DOI: 10.3892/or.2019.7289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
126 Kardideh B, Samimi Z, Norooznezhad F, Kiani S, Mansouri K. Autophagy, cancer and angiogenesis: where is the link? Cell Biosci 2019;9:65. [PMID: 31428311 DOI: 10.1186/s13578-019-0327-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
127 Jafarian AH, Kooshkiforooshani M, Rasoliostadi A, Mohamadian Roshan N. Vascular Mimicry Expression in Invasive Ductal Carcinoma; A New Technique for Prospect of Aggressiveness. Iran J Pathol 2019;14:232-5. [PMID: 31583000 DOI: 10.30699/ijp.2019.94997.1939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
128 Fuller AM, Olsson LT, Midkiff BR, Kirk EL, McNaughton KK, Calhoun BC, Troester MA. Vascular density of histologically benign breast tissue from women with breast cancer: associations with tissue composition and tumor characteristics. Hum Pathol 2019;91:43-51. [PMID: 31271812 DOI: 10.1016/j.humpath.2019.06.003] [Reference Citation Analysis]
129 Wang Y, Yu H, Zhang D, Wang G, Song W, Liu Y, Ma S, Tang Z, Liu Z, Sakurai K, Chen X. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma. Acta Biomater 2019;92:229-40. [PMID: 31100462 DOI: 10.1016/j.actbio.2019.05.028] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
130 Abma E, Stock E, De Spiegelaere W, Van Brantegem L, Vanderperren K, Ni Y, Vynck M, Daminet S, De Clercq K, de Rooster H. Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients. Sci Rep 2019;9:9262. [PMID: 31239493 DOI: 10.1038/s41598-019-45682-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
131 Marijt KA, Sluijter M, Blijleven L, Tolmeijer SH, Scheeren FA, van der Burg SH, van Hall T. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling. J Immunother Cancer 2019;7:152. [PMID: 31196219 DOI: 10.1186/s40425-019-0627-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
132 Gill JH, Rockley KL, De Santis C, Mohamed AK. Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics. Pharmacol Ther 2019;202:18-31. [PMID: 31173840 DOI: 10.1016/j.pharmthera.2019.06.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
133 Shi L, Liu P, Wu J, Ma L, Zheng H, Antosh MP, Zhang H, Wang B, Chen W, Wang X. The effectiveness and safety of X-PDT for cutaneous squamous cell carcinoma and melanoma. Nanomedicine (Lond) 2019;14:2027-43. [PMID: 31165659 DOI: 10.2217/nnm-2019-0094] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
134 Krishnapriya S, Malipatil B, Surekha S, Sundersingh S, Sridevi V, Ananthi B, Selvaluxmy G, Ganesan TS. Microvessel Density (MVD) in Locally Advanced Breast Cancer. Asian Pac J Cancer Prev 2019;20:1537-45. [PMID: 31128060 DOI: 10.31557/APJCP.2019.20.5.1537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
135 Niu H, Strecker TE, Gerberich JL, Campbell JW 3rd, Saha D, Mondal D, Hamel E, Chaplin DJ, Mason RP, Trawick ML, Pinney KG. Structure Guided Design, Synthesis, and Biological Evaluation of Novel Benzosuberene Analogues as Inhibitors of Tubulin Polymerization. J Med Chem 2019;62:5594-615. [PMID: 31059248 DOI: 10.1021/acs.jmedchem.9b00551] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
136 Yang LQ, Li RY, Yang XY, Cui QF, Wang FY, Lin GQ, Zhang JG. Co-administration of Shexiang Baoxin Pill and Chemotherapy Drugs Potentiated Cancer Therapy by Vascular-Promoting Strategy. Front Pharmacol 2019;10:565. [PMID: 31178734 DOI: 10.3389/fphar.2019.00565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
137 Chen H, Liu D, Li Y, Xu X, Xu J, Yadav NN, Zhou S, van Zijl PCM, Liu G. CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans. Magn Reson Med 2019;82:1471-9. [PMID: 31106918 DOI: 10.1002/mrm.27818] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
138 Tanaka M, Siemann DW. Axl signaling is an important mediator of tumor angiogenesis. Oncotarget 2019;10:2887-98. [PMID: 31080559 DOI: 10.18632/oncotarget.26882] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
139 Zhang YX, Zhao YY, Shen J, Sun X, Liu Y, Liu H, Wang Y, Wang J. Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Nano Lett 2019;19:2774-83. [PMID: 30943039 DOI: 10.1021/acs.nanolett.8b04296] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 18.7] [Reference Citation Analysis]
140 Sun CW, Wu LC, Wankhede M, Wang D, Thoerner J, Woody L, Sorg BS, Townes TM, Terman DS. Exogenous sickle erythrocytes combined with vascular disruption trigger disseminated tumor vaso-occlusion and lung tumor regression. JCI Insight 2019;4:125535. [PMID: 30944254 DOI: 10.1172/jci.insight.125535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
141 Huang C, Lowerison MR, Lucien F, Gong P, Wang D, Song P, Chen S. Noninvasive Contrast-Free 3D Evaluation of Tumor Angiogenesis with Ultrasensitive Ultrasound Microvessel Imaging. Sci Rep 2019;9. [DOI: 10.1038/s41598-019-41373-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
142 Wolfram J, Ferrari M. Clinical Cancer Nanomedicine. Nano Today 2019;25:85-98. [PMID: 31360214 DOI: 10.1016/j.nantod.2019.02.005] [Cited by in Crossref: 144] [Cited by in F6Publishing: 120] [Article Influence: 48.0] [Reference Citation Analysis]
143 Ivanir E, Shachaf Y, Mironi‐harpaz I, Yeheskely‐hayon D, Hazanov L, Harpaz‐segev S, Birman T, Minai L, Melino S, Yelin D, Seliktar D. A Gel‐Based Model of Selective Cell Motility: Implications for Cell Sorting, Diagnostics, and Screening. Adv Funct Mater 2020;30:1807106. [DOI: 10.1002/adfm.201807106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Limeres MJ, Moretton MA, Bernabeu E, Chiappetta DA, Cuestas ML. Thinking small, doing big: Current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer. Materials Science and Engineering: C 2019;95:328-41. [DOI: 10.1016/j.msec.2018.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
145 Liang J, Ma R, Chen H, Zhang D, Ye W, Shi C, Luo L. Detection of Hyperacute Reactions of Desacetylvinblastine Monohydrazide in a Xenograft Model Using Intravoxel Incoherent Motion DWI and R2* Mapping. AJR Am J Roentgenol 2019;212:717-26. [PMID: 30699010 DOI: 10.2214/AJR.18.20517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
146 Gonawala S, Aryal M, Ewing JR, deCarvalho AC, Kalkanis S, Ali MM. MRI Monitoring of Cerebral Blood Flow after the Delivery of Nanocombretastatin across the Blood Brain Tumor Barrier. J Nanomed Nanotechnol 2018;9:516. [PMID: 30656065 DOI: 10.4172/2157-7439.1000516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
147 Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl 2019;98:1252-76. [PMID: 30813007 DOI: 10.1016/j.msec.2019.01.066] [Cited by in Crossref: 181] [Cited by in F6Publishing: 158] [Article Influence: 60.3] [Reference Citation Analysis]
148 Kutova OM, Guryev EL, Sokolova EA, Alzeibak R, Balalaeva IV. Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency. Cancers (Basel) 2019;11:E68. [PMID: 30634580 DOI: 10.3390/cancers11010068] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 14.0] [Reference Citation Analysis]
149 Mckenzie LK, Bryant HE, Weinstein JA. Transition metal complexes as photosensitisers in one- and two-photon photodynamic therapy. Coordination Chemistry Reviews 2019;379:2-29. [DOI: 10.1016/j.ccr.2018.03.020] [Cited by in Crossref: 134] [Cited by in F6Publishing: 83] [Article Influence: 44.7] [Reference Citation Analysis]
150 Nussbaum LA, Kallmes KM, Bellairs E, McDonald W, Nussbaum ES. De novo cavernous malformation arising in the wall of vestibular schwannoma following stereotactic radiosurgery: case report and review of the literature. Acta Neurochir (Wien) 2019;161:49-55. [PMID: 30430258 DOI: 10.1007/s00701-018-3734-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
151 Swetha KL, Roy A. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization. Drug Deliv Transl Res 2018;8:1508-26. [PMID: 30128797 DOI: 10.1007/s13346-018-0578-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
152 Mondal D, Niu H, Pinney KG. Efficient Synthetic Methodology for the Construction of Dihydronaphthalene and Benzosuberene Molecular Frameworks. Tetrahedron Lett 2019;60:397-401. [PMID: 31061544 DOI: 10.1016/j.tetlet.2018.12.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
153 Yeldag G, Rice A, Del Río Hernández A. Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers (Basel) 2018;10:E471. [PMID: 30487436 DOI: 10.3390/cancers10120471] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis]
154 Tantyo NA, Karyadi AS, Rasman SZ, Salim MRG, Devina A, Sumarpo A. The prognostic value of S100A10 expression in cancer. Oncol Lett 2019;17:1417-24. [PMID: 30675195 DOI: 10.3892/ol.2018.9751] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
155 Schmitt F, Gold M, Rothemund M, Andronache I, Biersack B, Schobert R, Mueller T. New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents. Eur J Med Chem 2019;163:160-8. [PMID: 30503940 DOI: 10.1016/j.ejmech.2018.11.055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
156 Prasad B, Lakshma Nayak V, Srikanth PS, Baig MF, Subba Reddy NV, Babu KS, Kamal A. Synthesis and biological evaluation of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides as antimitotic agents. Bioorg Chem 2019;83:535-48. [PMID: 30472555 DOI: 10.1016/j.bioorg.2018.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
157 Vicente-Blázquez A, González M, Álvarez R, Del Mazo S, Medarde M, Peláez R. Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target. Med Res Rev 2019;39:775-830. [PMID: 30362234 DOI: 10.1002/med.21541] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
158 Liang J, Luo Q, Zhang D, Jin Q, Liu L, Liu W, Gao M, Zhang J, Yin Z. SPECT Imaging of Treatment-Related Tumor Necrosis Using Technetium-99m-Labeled Rhein. Mol Imaging Biol 2019;21:660-8. [DOI: 10.1007/s11307-018-1285-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
159 Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine 2018;13:6049-58. [PMID: 30323592 DOI: 10.2147/IJN.S140462] [Cited by in Crossref: 143] [Cited by in F6Publishing: 79] [Article Influence: 35.8] [Reference Citation Analysis]
160 Macor P, Capolla S, Tedesco F. Complement as a Biological Tool to Control Tumor Growth. Front Immunol 2018;9:2203. [PMID: 30319647 DOI: 10.3389/fimmu.2018.02203] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
161 As MN, Deshpande R, Kale VP, Bhonde RR, Datar SP. Establishment of an in ovo chick embryo yolk sac membrane (YSM) assay for pilot screening of potential angiogenic and anti-angiogenic agents. Cell Biol Int 2018;42:1474-83. [PMID: 30136736 DOI: 10.1002/cbin.11051] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
162 Nabaei M, Karimi M. Numerical investigation of the effect of vessel size and distance on the cryosurgery of an adjacent tumor. J Therm Biol 2018;77:45-54. [PMID: 30196898 DOI: 10.1016/j.jtherbio.2018.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
163 Zhang H, Fang X, Meng Q, Mao Y, Xu Y, Fan T, An J, Huang Z. Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities. European Journal of Medicinal Chemistry 2018;157:380-96. [DOI: 10.1016/j.ejmech.2018.07.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
164 Álvarez R, Gajate C, Puebla P, Mollinedo F, Medarde M, Peláez R. Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells. Eur J Med Chem 2018;158:167-83. [PMID: 30216850 DOI: 10.1016/j.ejmech.2018.08.078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
165 Maguire CJ, Chen Z, Mocharla VP, Sriram M, Strecker TE, Hamel E, Zhou H, Lopez R, Wang Y, Mason RP, Chaplin DJ, Trawick ML, Pinney KG. Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents. Medchemcomm 2018;9:1649-62. [PMID: 30429970 DOI: 10.1039/c8md00322j] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
166 Mondal D, Ford J, Pinney KG. Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research. Tetrahedron Lett 2018;59:3594-9. [PMID: 31156276 DOI: 10.1016/j.tetlet.2018.08.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
167 Lacroix R, Rozeman EA, Kreutz M, Renner K, Blank CU. Targeting tumor-associated acidity in cancer immunotherapy. Cancer Immunol Immunother 2018;67:1331-48. [PMID: 29974196 DOI: 10.1007/s00262-018-2195-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
168 Zhu S, Gu Z, Zhao Y. Harnessing Tumor Microenvironment for Nanoparticle-Mediated Radiotherapy. Adv Therap 2018;1:1800050. [DOI: 10.1002/adtp.201800050] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
169 Coughlin TR, Romero-Moreno R, Mason DE, Nystrom L, Boerckel JD, Niebur G, Littlepage LE. Bone: A Fertile Soil for Cancer Metastasis. Curr Drug Targets 2017;18:1281-95. [PMID: 28025941 DOI: 10.2174/1389450117666161226121650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
170 Macchini M, Ponziani M, Iamurri AP, Pistelli M, De Lisa M, Berardi R, Giuseppetti GM. Role of DCE-MR in predicting breast cancer subtypes. Radiol Med 2018;123:753-64. [PMID: 29869226 DOI: 10.1007/s11547-018-0908-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
171 Kinstlinger IS, Miller JS. 3D-printed fluidic networks as vasculature for engineered tissue. Lab Chip 2016;16:2025-43. [PMID: 27173478 DOI: 10.1039/c6lc00193a] [Cited by in Crossref: 78] [Cited by in F6Publishing: 30] [Article Influence: 19.5] [Reference Citation Analysis]
172 Abma E, De Spiegelaere W, Vanderperren K, Stock E, Van Brantegem L, Cornelis I, Daminet S, Ni Y, Vynck M, Verstraete G, Smets P, de Rooster H. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers. Vet Comp Oncol 2018;16:467-77. [PMID: 29797763 DOI: 10.1111/vco.12402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
173 El Bairi K, Amrani M, Afqir S. Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. Cancer Med 2018;7:2221-46. [PMID: 29732738 DOI: 10.1002/cam4.1467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
174 Li X, Zhen M, Deng R, Yu T, Li J, Zhang Y, Zou T, Zhou Y, Lu Z, Guan M, Xu H, Shu C, Wang C. RF-assisted gadofullerene nanoparticles induces rapid tumor vascular disruption by down-expression of tumor vascular endothelial cadherin. Biomaterials 2018;163:142-53. [DOI: 10.1016/j.biomaterials.2018.02.028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
175 Niland S, Komljenovic D, Macas J, Bracht T, Bäuerle T, Liebner S, Eble JA. Rhodocetin-αβ selectively breaks the endothelial barrier of the tumor vasculature in HT1080 fibrosarcoma and A431 epidermoid carcinoma tumor models. Oncotarget 2018;9:22406-22. [PMID: 29854288 DOI: 10.18632/oncotarget.25032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
176 Barbone GE, Bravin A, Romanelli P, Mittone A, Bucci D, Gaaβ T, Le Duc G, Auweter S, Reiser MF, Kraiger MJ, Hrabě de Angelis M, Battaglia G, Coan P. Micro-imaging of Brain Cancer Radiation Therapy Using Phase-contrast Computed Tomography. Int J Radiat Oncol Biol Phys 2018;101:965-84. [PMID: 29976510 DOI: 10.1016/j.ijrobp.2018.03.063] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
177 Yehya AHS, Asif M, Petersen SH, Subramaniam AV, Kono K, Majid AMSA, Oon CE. Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis. Medicina (Kaunas) 2018;54:E8. [PMID: 30344239 DOI: 10.3390/medicina54010008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
178 Hughes VS, Wiggins JM, Siemann DW. Tumor oxygenation and cancer therapy-then and now. Br J Radiol 2019;92:20170955. [PMID: 29513032 DOI: 10.1259/bjr.20170955] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
179 Niu Y, Zhu J, Li Y, Shi H, Gong Y, Li R, Huo Q, Ma T, Liu Y. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles. J Control Release 2018;277:35-47. [PMID: 29545106 DOI: 10.1016/j.jconrel.2018.03.012] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 15.5] [Reference Citation Analysis]
180 Bueno O, Estévez Gallego J, Martins S, Prota AE, Gago F, Gómez-SanJuan A, Camarasa MJ, Barasoain I, Steinmetz MO, Díaz JF, Pérez-Pérez MJ, Liekens S, Priego EM. High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design. Sci Rep 2018;8:4242. [PMID: 29523799 DOI: 10.1038/s41598-018-22382-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
181 Liu Y, Kim YJ, Siriwon N, Rohrs JA, Yu Z, Wanga P. Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature. Biotechnol Bioeng 2018;115:1403-15. [PMID: 29457630 DOI: 10.1002/bit.26566] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
182 Ho YT, Lee SWL, Azman N‘, Loh FWY, Phan Thien N, Kah JCY. Quantifying Vascular Distribution and Adhesion of Nanoparticles with Protein Corona in Microflow. Langmuir 2018;34:3731-41. [DOI: 10.1021/acs.langmuir.8b00322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
183 Zhang D, Gao M, Yao N, Jiang C, Liu W, Li T, Song S, Huang D, Yin Z, Qiu Y, Jin Q. Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents. Contrast Media Mol Imaging 2018;2018:5237950. [PMID: 29681781 DOI: 10.1155/2018/5237950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
184 Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15:310-324. [PMID: 29434333 DOI: 10.1038/nrclinonc.2018.9] [Cited by in Crossref: 168] [Cited by in F6Publishing: 175] [Article Influence: 42.0] [Reference Citation Analysis]
185 Banerjee S, Arnst KE, Wang Y, Kumar G, Deng S, Yang L, Li GB, Yang J, White SW, Li W, Miller DD. Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy. J Med Chem 2018;61:1704-18. [PMID: 29406710 DOI: 10.1021/acs.jmedchem.7b01858] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 15.5] [Reference Citation Analysis]
186 Niu F, Liu Y, Jing Z, Han G, Sun L, Yan L, Zhou L, Wu Y, Xu Y, Hu L, Zhao X. Novel carbazole sulfonamide microtubule-destabilizing agents exert potent antitumor activity against esophageal squamous cell carcinoma. Cancer Lett 2018;420:60-71. [PMID: 29408653 DOI: 10.1016/j.canlet.2018.01.066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
187 Kwong TC, Hsing M, Lin Y, Thayer D, Unlu MB, Su MY, Gulsen G. Differentiation of tumor vasculature heterogeneity levels in small animals based on total hemoglobin concentration using magnetic resonance-guided diffuse optical tomography in vivo. Appl Opt 2016;55:5479-87. [PMID: 27463894 DOI: 10.1364/AO.55.005479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
188 Park KM, Lewis D, Gerecht S. Bioinspired Hydrogels to Engineer Cancer Microenvironments. Annu Rev Biomed Eng 2017;19:109-33. [PMID: 28633560 DOI: 10.1146/annurev-bioeng-071516-044619] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
189 Karppinen SM, Honkanen HK, Heljasvaara R, Riihilä P, Autio-Harmainen H, Sormunen R, Harjunen V, Väisänen MR, Väisänen T, Hurskainen T, Tasanen K, Kähäri VM, Pihlajaniemi T. Collagens XV and XVIII show different expression and localisation in cutaneous squamous cell carcinoma: type XV appears in tumor stroma, while XVIII becomes upregulated in tumor cells and lost from microvessels. Exp Dermatol 2016;25:348-54. [PMID: 26660139 DOI: 10.1111/exd.12913] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
190 Varan G, Patrulea V, Borchard G, Bilensoy E. Cellular Interaction and Tumoral Penetration Properties of Cyclodextrin Nanoparticles on 3D Breast Tumor Model. Nanomaterials (Basel) 2018;8:E67. [PMID: 29373490 DOI: 10.3390/nano8020067] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
191 Daei Farshchi Adli A, Jahanban-esfahlan R, Seidi K, Samandari-rad S, Zarghami N. An overview on Vadimezan (DMXAA): The vascular disrupting agent. Chem Biol Drug Des 2018;91:996-1006. [DOI: 10.1111/cbdd.13166] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
192 Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract 2018;5:1. [PMID: 29318022 DOI: 10.1186/s40661-017-0058-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
193 Nishidate M, Yamamoto K, Masuda C, Aikawa H, Hayashi M, Kawanishi T, Hamada A. MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells. Sci Rep 2017;7:16763. [PMID: 29196706 DOI: 10.1038/s41598-017-17211-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
194 Eyarefe DO, Kuforiji DI, Jarikre TA, Emikpe BO. Enhanced electroscalpel incisional wound healing potential of honey in wistar rats. Int J Vet Sci Med 2017;5:128-34. [PMID: 30255061 DOI: 10.1016/j.ijvsm.2017.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
195 Cavaco A, Rezaei M, Niland S, Eble JA. Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy. Int J Mol Sci 2017;18:E2355. [PMID: 29112161 DOI: 10.3390/ijms18112355] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
196 Canela MD, Noppen S, Bueno O, Prota AE, Bargsten K, Sáez-Calvo G, Jimeno ML, Benkheil M, Ribatti D, Velázquez S, Camarasa MJ, Díaz JF, Steinmetz MO, Priego EM, Pérez-Pérez MJ, Liekens S. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091. Oncotarget 2017;8:14325-42. [PMID: 27224920 DOI: 10.18632/oncotarget.9527] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
197 Ojha T, Pathak V, Shi Y, Hennink WE, Moonen CTW, Storm G, Kiessling F, Lammers T. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv Drug Deliv Rev 2017;119:44-60. [PMID: 28697952 DOI: 10.1016/j.addr.2017.07.007] [Cited by in Crossref: 139] [Cited by in F6Publishing: 133] [Article Influence: 27.8] [Reference Citation Analysis]
198 Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. J Pharmacokinet Pharmacodyn 2017;44:521-36. [PMID: 28913666 DOI: 10.1007/s10928-017-9543-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
199 Siemann DW, Chaplin DJ, Horsman MR. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. Cancer Investigation 2017;35:519-34. [DOI: 10.1080/07357907.2017.1364745] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
200 Hou K, Fixler D, Han B, Shi L, Feder I, Duadi H, Wang X, Tang Z. Towards In Vivo Tumor Detection Using Polarization and Wavelength Characteristics of Self-Assembled Gold Nanorods. ChemNanoMat 2017;3:736-9. [DOI: 10.1002/cnma.201700157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
201 Weiss JM, Guérin MV, Regnier F, Renault G, Galy-Fauroux I, Vimeux L, Feuillet V, Peranzoni E, Thoreau M, Trautmann A, Bercovici N. The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. Oncoimmunology 2017;6:e1346765. [PMID: 29123960 DOI: 10.1080/2162402X.2017.1346765] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
202 Cui MT, Jiang L, Goto M, Hsu PL, Li L, Zhang Q, Wei L, Yuan SJ, Hamel E, Morris-Natschke SL, Lee KH, Xie L. In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents. J Med Chem 2017;60:5586-98. [PMID: 28653846 DOI: 10.1021/acs.jmedchem.7b00273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
203 Chiew GGY, Wei N, Sultania S, Lim S, Luo KQ. Bioengineered three-dimensional co-culture of cancer cells and endothelial cells: A model system for dual analysis of tumor growth and angiogenesis. Biotechnol Bioeng 2017;114:1865-77. [PMID: 28369747 DOI: 10.1002/bit.26297] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
204 Chase DM, Chaplin DJ, Monk BJ. The development and use of vascular targeted therapy in ovarian cancer. Gynecologic Oncology 2017;145:393-406. [DOI: 10.1016/j.ygyno.2017.01.031] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
205 Jain H, Jackson T. Mathematical Modeling of Cellular Cross-Talk Between Endothelial and Tumor Cells Highlights Counterintuitive Effects of VEGF-Targeted Therapies. Bull Math Biol 2018;80:971-1016. [DOI: 10.1007/s11538-017-0273-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
206 Manning T, Plummer S, Woods R, Wylie G, Phillips D, Krajewski L. Cell line studies and analytical measurements of three paclitaxel complex variations. Bioorg Med Chem Lett 2017;27:2793-9. [PMID: 28495086 DOI: 10.1016/j.bmcl.2017.04.070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
207 Chang CC, Chen HH, Chang YC, Yang MY, Lo CM, Ko WC, Lee YF, Liu KL, Chang RF. Computer-aided diagnosis of liver tumors on computed tomography images. Comput Methods Programs Biomed 2017;145:45-51. [PMID: 28552125 DOI: 10.1016/j.cmpb.2017.04.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 9.2] [Reference Citation Analysis]
208 Gupta S, Roy A, Dwarakanath BS. Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. Front Oncol 2017;7:68. [PMID: 28447025 DOI: 10.3389/fonc.2017.00068] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 13.8] [Reference Citation Analysis]
209 Shagufta, Ahmad I. An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. Medchemcomm 2017;8:871-85. [PMID: 30108803 DOI: 10.1039/c7md00097a] [Cited by in Crossref: 70] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
210 Darvishi B, Farahmand L, Majidzadeh-A K. Patterns of Cancer Stem Cell Negotiation with Breast Cancer Anti-angiogenic Therapy. Breast J 2017;23:612-4. [PMID: 28370769 DOI: 10.1111/tbj.12806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
211 Zamora A, Pérez SA, Rothemund M, Rodríguez V, Schobert R, Janiak C, Ruiz J. Exploring the Influence of the Aromaticity on the Anticancer and Antivascular Activities of Organoplatinum(II) Complexes. Chem Eur J 2017;23:5614-25. [DOI: 10.1002/chem.201700717] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
212 Rossington SB, Hadfield JA, Shnyder SD, Wallace TW, Williams KJ. Tubulin-binding dibenz[c,e]oxepines: Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents. Bioorg Med Chem 2017;25:1630-42. [PMID: 28143677 DOI: 10.1016/j.bmc.2017.01.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
213 Lv S, Tang Z, Song W, Zhang D, Li M, Liu H, Cheng J, Zhong W, Chen X. Inhibiting Solid Tumor Growth In Vivo by Non-Tumor-Penetrating Nanomedicine. Small 2017;13. [PMID: 28079981 DOI: 10.1002/smll.201600954] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
214 El-Sherbiny IM, Elbaz NM, Sedki M, Elgammal A, Yacoub MH. Magnetic nanoparticles-based drug and gene delivery systems for the treatment of pulmonary diseases. Nanomedicine (Lond) 2017;12:387-402. [PMID: 28078950 DOI: 10.2217/nnm-2016-0341] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
215 Lee N, Kim D. Cancer Metabolism: Fueling More than Just Growth. Mol Cells 2016;39:847-54. [PMID: 28030896 DOI: 10.14348/molcells.2016.0310] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
216 Fruytier AC, Le Duff CS, Po C, Magat J, Bouzin C, Neveu MA, Feron O, Jordan BF, Gallez B. The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma. Front Pharmacol 2016;7:506. [PMID: 28066252 DOI: 10.3389/fphar.2016.00506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
217 Winn BA, Shi Z, Carlson GJ, Wang Y, Nguyen BL, Kelly EM, Ross RD 4th, Hamel E, Chaplin DJ, Trawick ML, Pinney KG. Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia. Bioorg Med Chem Lett 2017;27:636-41. [PMID: 28007448 DOI: 10.1016/j.bmcl.2016.11.093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
218 Banerjee S, Hwang DJ, Li W, Miller DD. Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis. Molecules 2016;21:E1468. [PMID: 27827858 DOI: 10.3390/molecules21111468] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
219 Chia PL, Russell PA, Scott AM, John T. Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma. Expert Review of Anticancer Therapy 2016;16:1235-45. [DOI: 10.1080/14737140.2016.1244008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
220 Herdman CA, Devkota L, Lin CM, Niu H, Strecker TE, Lopez R, Liu L, George CS, Tanpure RP, Hamel E, Chaplin DJ, Mason RP, Trawick ML, Pinney KG. Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization. Bioorg Med Chem 2015;23:7497-520. [PMID: 26775540 DOI: 10.1016/j.bmc.2015.10.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
221 Berbeco RI, Detappe A, Tsiamas P, Parsons D, Yewondwossen M, Robar J. Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy. Med Phys 2016;43:436. [PMID: 26745936 DOI: 10.1118/1.4938410] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
222 Herdman CA, Strecker TE, Tanpure RP, Chen Z, Winters A, Gerberich J, Liu L, Hamel E, Mason RP, Chaplin DJ, Trawick ML, Pinney KG. Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization. Medchemcomm 2016;7:2418-27. [PMID: 28217276 DOI: 10.1039/C6MD00459H] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 4.2] [Reference Citation Analysis]
223 Lindsay D, Garvey CM, Mumenthaler SM, Foo J. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Comput Biol 2016;12:e1005077. [PMID: 27560187 DOI: 10.1371/journal.pcbi.1005077] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
224 Cao L, Zhang L, Zhao X, Zhang Y. A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells. PLoS One 2016;11:e0161025. [PMID: 27525972 DOI: 10.1371/journal.pone.0161025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
225 Porcù E, Salvador A, Primac I, Mitola S, Ronca R, Ravelli C, Bortolozzi R, Vedaldi D, Romagnoli R, Basso G, Viola G. Vascular disrupting activity of combretastatin analogues. Vascular Pharmacology 2016;83:78-89. [DOI: 10.1016/j.vph.2016.05.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
226 Shi TT, Li G, Xiao HT. The Role of RhoJ in Endothelial Cell Biology and Tumor Pathology. Biomed Res Int 2016;2016:6386412. [PMID: 27556037 DOI: 10.1155/2016/6386412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
227 Pérez-pérez M, Priego E, Bueno O, Martins MS, Canela M, Liekens S. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth. J Med Chem 2016;59:8685-711. [DOI: 10.1021/acs.jmedchem.6b00463] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 15.2] [Reference Citation Analysis]
228 Luo X, Xu G, Wei J, Chen M, Zhang H, Li X. Tunable release of chemotherapeutic and vascular disrupting agents from injectable fiber fragments potentiates combination chemotherapy. Int J Pharm 2016;506:1-12. [PMID: 27091295 DOI: 10.1016/j.ijpharm.2016.04.037] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
229 Porcù E, Persano L, Ronca R, Mitola S, Bortolozzi R, Romagnoli R, Oliva P, Basso G, Viola G. The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation. Sci Rep 2016;6:27886. [PMID: 27292568 DOI: 10.1038/srep27886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
230 Behling K, Maguire WF, Di Gialleonardo V, Heeb LE, Hassan IF, Veach DR, Keshari KR, Gutin PH, Scheinberg DA, McDevitt MR. Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles. J Nucl Med 2016;57:1771-7. [PMID: 27261519 DOI: 10.2967/jnumed.116.173559] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
231 Nepali K, Ojha R, Lee HY, Liou JP. Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opin Investig Drugs 2016;25:917-36. [PMID: 27186892 DOI: 10.1080/13543784.2016.1189901] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
232 Sudhan DR, Rabaglino MB, Wood CE, Siemann DW. Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94. Clin Exp Metastasis 2016;33:461-73. [PMID: 27055649 DOI: 10.1007/s10585-016-9790-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
233 Goins B, Phillips WT, Bao A. Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy. Expert Opin Drug Deliv 2016;13:873-89. [PMID: 26981891 DOI: 10.1517/17425247.2016.1167035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
234 Johnson SP, Ramasawmy R, Campbell-Washburn AE, Wells JA, Robson M, Rajkumar V, Lythgoe MF, Pedley RB, Walker-Samuel S. Acute changes in liver tumour perfusion measured non-invasively with arterial spin labelling. Br J Cancer 2016;114:897-904. [PMID: 27031853 DOI: 10.1038/bjc.2016.51] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
235 Han F, Wang P, Zhang W, Li J, Zhang Q, Qi X, Liu M. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization. Biomed Pharmacother 2016;80:151-61. [PMID: 27133052 DOI: 10.1016/j.biopha.2016.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
236 Chang RF, Chen HH, Chang YC, Huang CS, Chen JH, Lo CM. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. Magn Reson Imaging. 2016;34:809-819. [PMID: 26968141 DOI: 10.1016/j.mri.2016.03.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
237 Close A. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility. Future Medicinal Chemistry 2016;8:443-62. [DOI: 10.4155/fmc.16.6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
238 Castañeda-Gill JM, Vishwanatha JK. Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinog 2016;15:1. [PMID: 27013929 DOI: 10.4103/1477-3163.176223] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
239 Lewis DM, Gerecht S. Microfluidics and biomaterials to study angiogenesis. Current Opinion in Chemical Engineering 2016;11:114-22. [DOI: 10.1016/j.coche.2016.02.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
240 Devkota L, Lin CM, Strecker TE, Wang Y, Tidmore JK, Chen Z, Guddneppanavar R, Jelinek CJ, Lopez R, Liu L, Hamel E, Mason RP, Chaplin DJ, Trawick ML, Pinney KG. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents. Bioorg Med Chem 2016;24:938-56. [PMID: 26852340 DOI: 10.1016/j.bmc.2016.01.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
241 Canela M, Bueno O, Noppen S, Sáez Calvo G, Estévez Gallego J, Díaz JF, Camarasa M, Liekens S, Pérez-pérez M, Priego E. Targeting the colchicine site in tubulin through cyclohexanedione derivatives. RSC Adv 2016;6:19492-506. [DOI: 10.1039/c5ra26807a] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
242 Toro Bejarano M, Merchan JR. Targeting tumor vasculature through oncolytic virotherapy: recent advances. Oncolytic Virother 2015;4:169-81. [PMID: 27512680 DOI: 10.2147/OV.S66045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
243 Ke Q, Samad MA, Bae S, Chaplin DJ, Kang PM. Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem. Vascular Pharmacology 2015;74:73-9. [DOI: 10.1016/j.vph.2015.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
244 Schuemann J, Berbeco R, Chithrani DB, Cho SH, Kumar R, McMahon SJ, Sridhar S, Krishnan S. Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. Int J Radiat Oncol Biol Phys 2016;94:189-205. [PMID: 26700713 DOI: 10.1016/j.ijrobp.2015.09.032] [Cited by in Crossref: 120] [Cited by in F6Publishing: 104] [Article Influence: 17.1] [Reference Citation Analysis]
245 Seda R, Li DS, Fowlkes JB, Bull JL. Characterization of Bioeffects on Endothelial Cells under Acoustic Droplet Vaporization. Ultrasound Med Biol 2015;41:3241-52. [PMID: 26403698 DOI: 10.1016/j.ultrasmedbio.2015.07.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
246 Strecker TE, Odutola SO, Lopez R, Cooper MS, Tidmore JK, Charlton-Sevcik AK, Li L, MacDonough MT, Hadimani MB, Ghatak A, Liu L, Chaplin DJ, Mason RP, Pinney KG, Trawick ML. The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts. Cancer Lett 2015;369:229-41. [PMID: 26325604 DOI: 10.1016/j.canlet.2015.08.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
247 Stahel R, Weder W, Felley-bosco E, Petrausch U, Curioni-fontecedro A, Schmitt-opitz I, Peters S. Searching for targets for the systemic therapy of mesothelioma. Annals of Oncology 2015;26:1649-60. [DOI: 10.1093/annonc/mdv101] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
248 Roccarina D, Garcovich M, Ainora ME, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World J Hepatol 2015; 7(14): 1866-1874 [PMID: 26207168 DOI: 10.4254/wjh.v7.i14.1866] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
249 Wang SB, Wang XF, Qin B, Ohkoshi E, Hsieh KY, Hamel E, Cui MT, Zhu DQ, Goto M, Morris-Natschke SL, Lee KH, Xie L. Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors. Bioorg Med Chem 2015;23:5740-7. [PMID: 26242242 DOI: 10.1016/j.bmc.2015.07.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
250 Weiss WA, Medved M, Karczmar GS, Giger ML. Preliminary assessment of dispersion versus absorption analysis of high spectral and spatial resolution magnetic resonance images in the diagnosis of breast cancer. J Med Imaging (Bellingham) 2015;2:024502. [PMID: 26158106 DOI: 10.1117/1.JMI.2.2.024502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
251 Williams LJ, Mukherjee D, Fisher M, Reyes-Aldasoro CC, Akerman S, Kanthou C, Tozer GM. An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate. Br J Pharmacol 2014;171:4902-13. [PMID: 24930520 DOI: 10.1111/bph.12817] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
252 Porcù E, Bortolozzi R, Basso G, Viola G. Recent advances in vascular disrupting agents in cancer therapy. Future Med Chem 2014;6:1485-98. [PMID: 25365233 DOI: 10.4155/fmc.14.104] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
253 Lee H, Kim DG, Banskota S, Lee YK, Nam TG, Kim JA, Jeong BS. Pyridoxine-derived bicyclic amido-, ureido-, and carbamato-pyridinols: synthesis and antiangiogenic activities. Org Biomol Chem 2014;12:8702-10. [PMID: 25255328 DOI: 10.1039/c4ob01221f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
254 Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther 2015;153:107-24. [PMID: 26073310 DOI: 10.1016/j.pharmthera.2015.06.006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
255 Yao N, Ren K, Jiang C, Gao M, Huang D, Lu X, Lou B, Peng F, Yang A, Wang X, Ni Y, Zhang J. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo. Tumor Biol 2015;36:8499-510. [DOI: 10.1007/s13277-015-3508-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
256 Abma E, Daminet S, Smets P, Ni Y, de Rooster H. Combretastatin A4-phosphate and its potential in veterinary oncology: a review. Vet Comp Oncol 2017;15:184-93. [PMID: 25988493 DOI: 10.1111/vco.12150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
257 Quek R. Tumour vascular-disrupting agents in soft-tissue sarcoma. The Lancet Oncology 2015;16:480-1. [DOI: 10.1016/s1470-2045(15)70139-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
258 Wang F, Yang Z, Liu Y, Ma L, Wu Y, He L, Shao M, Yu K, Wu W, Pu Y, Nie C, Chen L. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity. Bioorg Med Chem 2015;23:3337-50. [PMID: 25937236 DOI: 10.1016/j.bmc.2015.04.055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
259 Blay JY, Pápai Z, Tolcher AW, Italiano A, Cupissol D, López-Pousa A, Chawla SP, Bompas E, Babovic N, Penel N, Isambert N, Staddon AP, Saâda-Bouzid E, Santoro A, Franke FA, Cohen P, Le-Guennec S, Demetri GD. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:531-40. [PMID: 25864104 DOI: 10.1016/S1470-2045(15)70102-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 5.9] [Reference Citation Analysis]
260 Goertz DE. An overview of the influence of therapeutic ultrasound exposures on the vasculature: high intensity ultrasound and microbubble-mediated bioeffects. Int J Hyperthermia 2015;31:134-44. [PMID: 25716770 DOI: 10.3109/02656736.2015.1009179] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
261 Oh DY, Kim TM, Han SW, Shin DY, Lee YG, Lee KW, Kim JH, Kim TY, Jang IJ, Lee JS, Bang YJ. Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. Cancer Res Treat 2016;48:28-36. [PMID: 25715767 DOI: 10.4143/crt.2014.258] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
262 Stéphanou A, Le Floc’h S, Chauvière A, Stephanou A, Volpert V. A Hybrid Model to Test the Importance of Mechanical Cues Driving Cell Migration in Angiogenesis. Math Model Nat Phenom 2015;10:142-66. [DOI: 10.1051/mmnp/201510107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
263 Krishnamurthy S, Vaiyapuri R, Zhang L, Chan JM. Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater Sci 2015;3:923-36. [PMID: 26221931 DOI: 10.1039/c4bm00427b] [Cited by in Crossref: 83] [Cited by in F6Publishing: 19] [Article Influence: 11.9] [Reference Citation Analysis]
264 Goldwirt L, Beccaria K, Carpentier A, Idbaih A, Schmitt C, Levasseur C, Labussiere M, Milane A, Farinotti R, Fernandez C. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. J Neurooncol 2015;122:273-81. [PMID: 25794638 DOI: 10.1007/s11060-015-1717-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
265 Wang Z, Kerketta R, Chuang YL, Cristini V. Development of a diffusion-based mathematical model for predicting chemotherapy effects. Annu Int Conf IEEE Eng Med Biol Soc 2014;2014:2480-3. [PMID: 25570493 DOI: 10.1109/EMBC.2014.6944125] [Reference Citation Analysis]
266 Huang C, Qin H, Qian J, Zhang J, Zhao S, Changyi Y, Li B, Zhang J, Zhu J, Xing D, Yang S, Li C. Multi-parametric imaging of the invasiveness-permissive acidic microenvironment in human glioma xenografts. RSC Adv 2015;5:55669-77. [DOI: 10.1039/c5ra07685d] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
267 Yan GH, Li XF, Ge BC, Shi XD, Chen YF, Yang XM, Xu JP, Liu SW, Zhao PL, Zhou ZZ, Zhou CQ, Chen WH. Synthesis and anticancer activities of 3-arylflavone-8-acetic acid derivatives. Eur J Med Chem 2015;90:251-7. [PMID: 25461325 DOI: 10.1016/j.ejmech.2014.11.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
268 Zhuang X, Ahmed F, Zhang Y, Ferguson HJ, Steele JC, Steven NM, Nagy Z, Heath VL, Toellner KM, Bicknell R. Robo4 vaccines induce antibodies that retard tumor growth. Angiogenesis 2015;18:83-95. [PMID: 25348086 DOI: 10.1007/s10456-014-9448-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
269 Biel NM, Siemann DW. Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett 2016;380:525-33. [PMID: 25312939 DOI: 10.1016/j.canlet.2014.09.035] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
270 Liu L, Mason RP, Gimi B. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts. Cancer Lett 2015;356:462-9. [PMID: 25305449 DOI: 10.1016/j.canlet.2014.09.038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
271 Hori K, Akita H, Nonaka H, Sumiyoshi A, Taki Y. Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface. Cancer Sci 2014;105:1196-204. [PMID: 24981848 DOI: 10.1111/cas.12477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
272 Luo X, Zhang H, Chen M, Wei J, Zhang Y, Li X. Antimetastasis and antitumor efficacy promoted by sequential release of vascular disrupting and chemotherapeutic agents from electrospun fibers. Int J Pharm 2014;475:438-49. [PMID: 25218185 DOI: 10.1016/j.ijpharm.2014.09.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
273 Lee JA, Biel NM, Kozikowski RT, Siemann DW, Sorg BS. In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors. Biomed Opt Express 2014;5:1965-79. [PMID: 24940553 DOI: 10.1364/BOE.5.001965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
274 von Pawel J, Gorbounova V, Reck M, Kowalski DM, Allard A, Chadjaa M, Rey A, Bennouna J, Grossi F; DISRUPT Investigators. DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer. Lung Cancer 2014;85:224-9. [PMID: 24888230 DOI: 10.1016/j.lungcan.2014.05.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
275 Lee H, Banskota S, Kim DG, Been JH, Jin YJ, Gautam J, Jang H, Nam TG, Kim JA, Jeong BS. Synthesis and antiangiogenic activity of 6-amido-2,4,5-trimethylpyridin-3-ols. Bioorg Med Chem Lett 2014;24:3131-6. [PMID: 24894557 DOI: 10.1016/j.bmcl.2014.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
276 Canela MD, Pérez-Pérez MJ, Noppen S, Sáez-Calvo G, Díaz JF, Camarasa MJ, Liekens S, Priego EM. Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach. J Med Chem 2014;57:3924-38. [PMID: 24773591 DOI: 10.1021/jm401939g] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
277 Lundström U, Westermark UK, Larsson DH, Burvall A, Arsenian Henriksson M, Hertz HM. X-ray phase contrast with injected gas for tumor microangiography. Phys Med Biol 2014;59:2801-11. [PMID: 24801363 DOI: 10.1088/0031-9155/59/11/2801] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
278 Chang C, Chuang H, Lee H, Yeh T, Kuo C, Chang C, Chang J, Liou J. Antimitotic and vascular disrupting agents: 2-Hydroxy-3,4,5-trimethoxybenzophenones. European Journal of Medicinal Chemistry 2014;77:306-14. [DOI: 10.1016/j.ejmech.2014.02.061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
279 Chen S, Huang EH. The colon cancer stem cell microenvironment holds keys to future cancer therapy. J Gastrointest Surg 2014;18:1040-8. [PMID: 24643495 DOI: 10.1007/s11605-014-2497-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
280 Muenzner JK, Biersack B, Kalie H, Andronache IC, Kaps L, Schuppan D, Sasse F, Schobert R. Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential. ChemMedChem 2014;9:1195-204. [PMID: 24648184 DOI: 10.1002/cmdc.201400049] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
281 Kim DG, Kang Y, Lee H, Lee EK, Nam TG, Kim JA, Jeong BS. 6-Amino-2,4,5-trimethylpyridin-3-ols: a new general synthetic route and antiangiogenic activity. Eur J Med Chem 2014;78:126-39. [PMID: 24681390 DOI: 10.1016/j.ejmech.2014.03.045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
282 Mahal K, Resch M, Ficner R, Schobert R, Biersack B, Mueller T. Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels. ChemMedChem 2014;9:847-54. [PMID: 24678059 DOI: 10.1002/cmdc.201300531] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
283 Wang XF, Guan F, Ohkoshi E, Guo W, Wang L, Zhu DQ, Wang SB, Wang LT, Hamel E, Yang D, Li L, Qian K, Morris-Natschke SL, Yuan S, Lee KH, Xie L. Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site. J Med Chem 2014;57:1390-402. [PMID: 24502232 DOI: 10.1021/jm4016526] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
284 Tsyganov DV, Khrustalev VN, Konyushkin LD, Raihstat MM, Firgang SI, Semenov RV, Kiselyov AS, Semenova MN, Semenov VV. 3-(5-)-Amino-o-diarylisoxazoles: Regioselective synthesis and antitubulin activity. European Journal of Medicinal Chemistry 2014;73:112-25. [DOI: 10.1016/j.ejmech.2013.12.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
285 Zhou ZZ, Gu CP, Deng YH, Yan GH, Li XF, Yu L, Chen WH, Liu SW. Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids. Bioorg Med Chem 2014;22:1539-47. [PMID: 24518295 DOI: 10.1016/j.bmc.2014.01.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
286 Jain HV, Richardson A, Meyer-Hermann M, Byrne HM. Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas. PLoS One 2014;9:e81582. [PMID: 24400068 DOI: 10.1371/journal.pone.0081582] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
287 Bindu PJ, Mahadevan KM, Naik TRR, Harish BG. Synthesis, DNA binding, docking and photocleavage studies of quinolinyl chalcones. Med Chem Commun 2014;5:1708-17. [DOI: 10.1039/c4md00185k] [Cited by in Crossref: 11] [Article Influence: 1.4] [Reference Citation Analysis]
288 Kim C, Yang H, Fukushima Y, Saw P, Lee J, Park J, Park I, Jung J, Kataoka H, Lee D, Do heo W, Kim I, Jon S, Adams RH, Nishikawa S, Uemura A, Koh G. Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption. Cancer Cell 2014;25:102-17. [DOI: 10.1016/j.ccr.2013.12.010] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 9.5] [Reference Citation Analysis]
289 Hervault A, Thanh NTK. Magnetic nanoparticle-based therapeutic agents for thermo-chemotherapy treatment of cancer. Nanoscale 2014;6:11553-73. [DOI: 10.1039/c4nr03482a] [Cited by in Crossref: 345] [Cited by in F6Publishing: 65] [Article Influence: 43.1] [Reference Citation Analysis]
290 Chen F, Keyzer FD, Feng YB, Cona MM, Yu J, Marchal G, Oyen R, Ni YC. Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats. World J Gastroenterol 2013; 19(47): 9092-9103 [PMID: 24379636 DOI: 10.3748/wjg.v19.i47.9092] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
291 Ferguson HJ, Wragg J, Ismail T, Bicknell R. Vaccination against tumour blood vessels in colorectal cancer. Eur J Surg Oncol 2014;40:133-6. [PMID: 24388410 DOI: 10.1016/j.ejso.2013.11.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
292 Demchuk DV, Samet AV, Chernysheva NB, Ushkarov VI, Stashina GA, Konyushkin LD, Raihstat MM, Firgang SI, Philchenkov AA, Zavelevich MP, Kuiava LM, Chekhun VF, Blokhin DY, Kiselyov AS, Semenova MN, Semenov VV. Synthesis and antiproliferative activity of conformationally restricted 1,2,3-triazole analogues of combretastatins in the sea urchin embryo model and against human cancer cell lines. Bioorg Med Chem 2014;22:738-55. [PMID: 24387982 DOI: 10.1016/j.bmc.2013.12.015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 6.2] [Reference Citation Analysis]
293 Liu YM, Chen HL, Lee HY, Liou JP. Tubulin inhibitors: a patent review. Expert Opin Ther Pat 2014;24:69-88. [PMID: 24313741 DOI: 10.1517/13543776.2014.859247] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
294 Fixler D, Zalevsky Z. In Vivo Tumor Detection Using Polarization and Wavelength Reflection Characteristics of Gold Nanorods. Nano Lett 2013;13:6292-6. [DOI: 10.1021/nl403927c] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
295 Baker JH, Kyle AH, Bartels KL, Methot SP, Flanagan EJ, Balbirnie A, Cran JD, Minchinton AI. Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin. PLoS One 2013;8:e76832. [PMID: 24204680 DOI: 10.1371/journal.pone.0076832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
296 Tuncel S, Trivella A, Atilla D, Bennis K, Savoie H, Albrieux F, Delort L, Billard H, Dubois V, Ahsen V, Caldefie-chézet F, Richard C, Boyle RW, Ducki S, Dumoulin F. Assessing the Dual Activity of a Chalcone–Phthalocyanine Conjugate: Design, Synthesis, and Antivascular and Photodynamic Properties. Mol Pharmaceutics 2013;10:3706-16. [DOI: 10.1021/mp400207v] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
297 Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, Pavlakis N, Boyer M, Stockler MR. A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer 2013;81:422-7. [DOI: 10.1016/j.lungcan.2013.05.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
298 Tsyganov DV, Konyushkin LD, Karmanova IB, Firgang SI, Strelenko YA, Semenova MN, Kiselyov AS, Semenov VV. cis -Restricted 3-Aminopyrazole Analogues of Combretastatins: Synthesis from Plant Polyalkoxybenzenes and Biological Evaluation in the Cytotoxicity and Phenotypic Sea Urchin Embryo Assays. J Nat Prod 2013;76:1485-91. [DOI: 10.1021/np400310m] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
299 Folaron M, Kalmuk J, Lockwood J, Frangou C, Vokes J, Turowski SG, Merzianu M, Rigual NR, Sullivan-Nasca M, Kuriakose MA, Hicks WL Jr, Singh AK, Seshadri M. Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. Oral Oncol 2013;49:893-902. [PMID: 23890930 DOI: 10.1016/j.oraloncology.2013.06.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
300 Mikstacka R, Stefański T, Różański J. Tubulin-interactive stilbene derivatives as anticancer agents. Cell Mol Biol Lett 2013;18:368-97. [PMID: 23818224 DOI: 10.2478/s11658-013-0094-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
301 Wang XF, Wang SB, Ohkoshi E, Wang LT, Hamel E, Qian K, Morris-Natschke SL, Lee KH, Xie L. N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin. Eur J Med Chem 2013;67:196-207. [PMID: 23867604 DOI: 10.1016/j.ejmech.2013.06.041] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
302 Pircher A, Fiegl M, Untergasser G, Heidegger I, Medinger M, Kern J, Hilbe W. Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs). Lung Cancer 2013;81:252-8. [PMID: 23664449 DOI: 10.1016/j.lungcan.2013.04.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
303 Kretzschmann VK, Fürst R. Plant-derived vascular disrupting agents: compounds, actions, and clinical trials. Phytochem Rev 2014;13:191-206. [DOI: 10.1007/s11101-013-9304-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
304 Shenoi MM, Iltis I, Choi J, Koonce NA, Metzger GJ, Griffin RJ, Bischof JC. Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm 2013;10:1683-94. [PMID: 23544801 DOI: 10.1021/mp300505w] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
305 Angarita FA, Acuna SA, Ottolino-Perry K, Zerhouni S, McCart JA. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses. Trends Mol Med 2013;19:378-92. [PMID: 23540715 DOI: 10.1016/j.molmed.2013.02.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
306 Markelc B, Sersa G, Cemazar M. Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels. PLoS One 2013;8:e59557. [PMID: 23555705 DOI: 10.1371/journal.pone.0059557] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 6.2] [Reference Citation Analysis]
307 Ty N, Pontikis R, Chabot GG, Devillers E, Quentin L, Bourg S, Florent J. Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4. Bioorganic & Medicinal Chemistry 2013;21:1357-66. [DOI: 10.1016/j.bmc.2012.11.056] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
308 Hoopes PJ, Petryk AA, Tate JA, Savellano MS, Strawbridge RR, Giustini AJ, Stan RV, Gimi B, Garwood M. Imaging and modification of the tumor vascular barrier for improvement in magnetic nanoparticle uptake and hyperthermia treatment efficacy. Proc SPIE Int Soc Opt Eng 2013;8584:858403. [PMID: 25285190 DOI: 10.1117/12.2008689] [Cited by in Crossref: 7] [Article Influence: 0.8] [Reference Citation Analysis]
309 Li J, Oyen R, Verbruggen A, Ni Y. Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications. J Cancer 2013;4:133-45. [PMID: 23412554 DOI: 10.7150/jca.5635] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
310 Goertz DE, Todorova M, Mortazavi O, Agache V, Chen B, Karshafian R, Hynynen K. Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles. PLoS One 2012;7:e52307. [PMID: 23284980 DOI: 10.1371/journal.pone.0052307] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
311 Clémenson C, Chargari C, Deutsch E. Combination of vascular disrupting agents and ionizing radiation. Crit Rev Oncol Hematol 2013;86:143-60. [PMID: 23177097 DOI: 10.1016/j.critrevonc.2012.10.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
312 Wu XY, Ma W, Gurung K, Guo CH. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy. J Formos Med Assoc. 2013;112:115-124. [PMID: 23473523 DOI: 10.1016/j.jfma.2012.09.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
313 Huang C, Pourgholami MH, Allen BJ. Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. Cancer Treatment Reviews 2012;38:854-60. [DOI: 10.1016/j.ctrv.2011.12.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
314 Koh PK, Faivre-finn C, Blackhall FH, De Ruysscher D. Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treatment Reviews 2012;38:626-40. [DOI: 10.1016/j.ctrv.2011.11.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
315 Hori K. Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism. Cancer Metastasis Rev 2012;31:109-22. [PMID: 22101805 DOI: 10.1007/s10555-011-9333-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
316 Liu L, Beck H, Wang X, Hsieh HP, Mason RP, Liu X. Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts. PLoS One 2012;7:e43314. [PMID: 22937031 DOI: 10.1371/journal.pone.0043314] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
317 Foley KP, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, Li H, Sang J, Korbut T, Ye J, Zhang X, Barsoum J, Sonderfan AJ. The Vascular Disrupting Agent STA-9584 Exhibits Potent Antitumor Activity by Selectively Targeting Microvasculature at Both the Center and Periphery of Tumors. J Pharmacol Exp Ther 2012;343:529-38. [DOI: 10.1124/jpet.112.196873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
318 Clémenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Invest New Drugs 2013;31:273-84. [PMID: 22810221 DOI: 10.1007/s10637-012-9852-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
319 Chen F, Feng Y, Zheng K, De Keyzer F, Li J, Feng Y, Cona MM, Wang H, Jiang Y, Yu J, Marchal G, Verfaillie C, De Geest B, Oyen R, Ni Y. Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI. PLoS One 2012;7:e41140. [PMID: 22815943 DOI: 10.1371/journal.pone.0041140] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
320 Wang H, Cona MM, Chen F, Yu J, Feng Y, Li J, Keyzer FD, Marchal G, Ni Y. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers. Anticancer Drugs 2012;23:12-21. [PMID: 21857503 DOI: 10.1097/CAD.0b013e328349dd60] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
321 Mur Blanch N, Chabot GG, Quentin L, Scherman D, Bourg S, Dauzonne D. In vitro and in vivo biological evaluation of new 4,5-disubstituted 1,2,3-triazoles as cis-constrained analogs of combretastatin A4. Eur J Med Chem 2012;54:22-32. [PMID: 22647220 DOI: 10.1016/j.ejmech.2012.04.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
322 Hollebecque A, Massard C, Soria J. Vascular disrupting agents: a delicate balance between efficacy and side effects. Current Opinion in Oncology 2012;24:305-15. [DOI: 10.1097/cco.0b013e32835249de] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
323 Adams DJ. The Valley of Death in anticancer drug development: a reassessment. Trends Pharmacol Sci 2012;33:173-80. [PMID: 22410081 DOI: 10.1016/j.tips.2012.02.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
324 Beale TM, Bond PJ, Brenton JD, Charnock-jones DS, Ley SV, Myers RM. Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A–1. Bioorganic & Medicinal Chemistry 2012;20:1749-59. [DOI: 10.1016/j.bmc.2012.01.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
325 Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, Verbruggen A, Ni Y. A review on various targeted anticancer therapies. Target Oncol 2012;7:69-85. [PMID: 22350489 DOI: 10.1007/s11523-012-0212-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
326 Da C, Telang N, Barelli P, Jia X, Gupton JT, Mooberry SL, Kellogg GE. Pyrrole-Based Antitubulin Agents: Two Distinct Binding Modalities are Predicted for C-2 Analogs in the Colchicine Site. ACS Med Chem Lett 2012;3:53-7. [PMID: 22611477 DOI: 10.1021/ml200217u] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
327 Tanpure RP, George CS, Sriram M, Strecker TE, Tidmore JK, Hamel E, Charlton-Sevcik AK, Chaplin DJ, Trawick ML, Pinney KG. An Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity. Medchemcomm 2012;3:720-4. [PMID: 23772309 DOI: 10.1039/C2MD00318J] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
328 Ngwa W, Makrigiorgos GM, Berbeco RI. Gold nanoparticle-aided brachytherapy with vascular dose painting: Estimation of dose enhancement to the tumor endothelial cell nucleus: Gold nanoparticle-aided brachytherapy with vascular dose painting. Med Phys 2012;39:392-8. [DOI: 10.1118/1.3671905] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
329 Deng ZT, Feng T, Wang P, Qi X, Chen XH, Li YX, Song CL, Geng MY, Li J. Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity. Biochem Pharmacol 2011;82:1832-42. [PMID: 21920350 DOI: 10.1016/j.bcp.2011.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
330 Shenoi MM, Shah NB, Griffin RJ, Vercellotti GM, Bischof JC. Nanoparticle preconditioning for enhanced thermal therapies in cancer. Nanomedicine (Lond) 2011;6:545-63. [PMID: 21542691 DOI: 10.2217/nnm.10.153] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
331 Cole L, Djidja M, Bluff J, Claude E, Carolan V, Paley M, Tozer G, Clench M. Investigation of protein induction in tumour vascular targeted strategies by MALDI MSI. Methods 2011;54:442-53. [DOI: 10.1016/j.ymeth.2011.03.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
332 Arthuis M, Pontikis R, Chabot GG, Seguin J, Quentin L, Bourg S, Morin-allory L, Florent J. Synthesis and Structure-Activity Relationships of Constrained Heterocyclic Analogues of Combretastatin A4. ChemMedChem 2011;6:1693-705. [DOI: 10.1002/cmdc.201100154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
333 Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, Durant S, Beesley JF, Herbert JM, Sheldon H, Andre M. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene. 2012;31:293-305. [PMID: 21706054 DOI: 10.1038/onc.2011.233] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
334 Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2965-71. [PMID: 21709202 DOI: 10.1200/JCO.2011.35.0660] [Cited by in Crossref: 193] [Cited by in F6Publishing: 93] [Article Influence: 17.5] [Reference Citation Analysis]
335 Titov IY, Sagamanova IK, Gritsenko RT, Karmanova IB, Atamanenko OP, Semenova MN, Semenov VV. Application of plant allylpolyalkoxybenzenes in synthesis of antimitotic phenstatin analogues. Bioorganic & Medicinal Chemistry Letters 2011;21:1578-81. [DOI: 10.1016/j.bmcl.2011.01.124] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
336 Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol (Camb) 2011;3:375-87. [PMID: 21321746 DOI: 10.1039/c0ib00135j] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
337 Tacon LJ, Prichard RS, Soon PS, Robinson BG, Clifton-Bligh RJ, Sidhu SB. Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist 2011;16:36-48. [PMID: 21212436 DOI: 10.1634/theoncologist.2010-0270] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
338 Semenov VV, Kiselyov AS, Titov IY, Sagamanova IK, Ikizalp NN, Chernysheva NB, Tsyganov DV, Konyushkin LD, Firgang SI, Semenov RV, Karmanova IB, Raihstat MM, Semenova MN. Synthesis of Antimitotic Polyalkoxyphenyl Derivatives of Combretastatin Using Plant Allylpolyalkoxybenzenes. J Nat Prod 2010;73:1796-802. [DOI: 10.1021/np1004278] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
339 Rice L, Pampo C, Lepler S, Rojiani AM, Siemann DW. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvasc Res 2011;81:44-51. [PMID: 20974154 DOI: 10.1016/j.mvr.2010.10.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]